Capricor Shares Fall, FDA Call in August Looms
Capricor Therapeutics shares moved lower in early trading Tuesday, following a 4.8% decline in the regular session. The rare-disease biotech is trading near $28.53 before the bell, as the stock stays focused on its looming U.S. regulatory date, not the broader market rally. Capricor’s current market value stands at around $1.64 billion. Capricor isn’t trading like a typical small-cap biotech anymore. Its valuation is tied to deramiocel, its experimental cell therapy for Duchenne muscular dystrophy, and the decision from the U.S. Food and Drug Administration, due by Aug. 22.